{
    "clinical_study": {
        "@rank": "21793", 
        "arm_group": [
            {
                "arm_group_label": "monosialotetrahexosylganglioside Sodium", 
                "arm_group_type": "Experimental", 
                "description": "arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant"
            }
        ], 
        "brief_summary": {
            "textblock": "The morbidity of colorectal cancer(CRC) is 10%\uff5e15% in China.mFolfox6 has become one of the\n      standard regimes for metastatic  colorectal cancer (mCRC). Neutropenia and\n      oxaliplatin-induced neurotoxicity are the most common adverse effects which even result in\n      discontinue of chemotherapy, especially for patients suffered from heavily acute\n      neurotoxicity. Monosialotetrahexosylganglioside is a component of membrane of nerve cells.\n      Previous phase II clinical trial showed, it can reduce oxaliplatin-induced\n      neurotoxicity(OIN). But it did not certificated by phase III trial. Investigators designed\n      the phase III trial to investigate the effect and safety of monosialotetrahexosylganglioside\n      Sodium Injection for prevention OIN at colorectal cancer."
        }, 
        "brief_title": "Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neurotoxicity Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "it is a placebo controlled phase III trial. investigators plan to enroll 240 patients with\n      1:1 to A arm and B arm"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients shall have normal organic function such as liver function, Cardiac function\n             and renal function;\n\n          2. age >18 years old;\n\n          3. diagnosis mCRC with histology;\n\n          4. Did not received first-line chemotherapy\n\n          5. Karnofsky Performance scores >70 scores\n\n          6. should have target lesions or non-target lesions\n\n          7. For patients received oxaliplatin before, the residual neurotoxicity should less than\n             grade 2\n\n          8. For diabetes without neuropathy, blood glucose before meal should less than 8mmol/L\n             and HBA1C<7.0%\n\n          9. Patients should be expected to live no shorter than 3 months\n\n        Exclusion Criteria:\n\n          1. patients who is receiving chemotherapy;\n\n          2. WBC\uff1c4.0\u00d7109/L\uff0cANC\uff1c1.5\u00d7109/L,PLT\uff1c100\u00d7109/L\uff0cHb\uff1c90g/L,TBIL\uff1e1.5Limitation;BUN\uff09\uff1e1.5Limitation\uff1bCr\uff09\uff1e1.5Limitation\uff1bALT or AST\uff1e2.5Limitation\uff08without liver metastasis\uff09\uff1bALT or AST\uff09\uff1e5Limitation\uff08with liver metastasis\uff09;\n\n          3. heart dysfunction;\n\n          4. brain metastasis;\n\n          5. peripheral nervous system or central nervous system abnormal including diabetes\n             mellitus patients with neuropathy;\n\n          6. patients who received Glutathione, acetylcysteine, calcium / magnesium, amifostine,\n             carbamazepine, B vitamins, vitamin E within 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024412", 
            "org_study_id": "20131123", 
            "secondary_id": "E2013109A"
        }, 
        "intervention": [
            {
                "arm_group_label": "monosialotetrahexosylganglioside Sodium", 
                "description": "it is a component extract from pig's brain,shenjie is the brand name", 
                "intervention_name": "monosialotetrahexosylganglioside Sodium", 
                "intervention_type": "Drug", 
                "other_name": "shenjie"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "saline of the same appearance as monosialotetrahexosylganglioside Sodium", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "saline"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "metastatic colorectal cancer", 
            "neurotoxicity", 
            "mFOLFOX6", 
            "monosialotetrahexosylganglioside Sodium Injection"
        ], 
        "lastchanged_date": "December 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300060"
                }, 
                "name": "Tianjin Medical University Cancer Institute and Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Colorectal Cancer", 
        "overall_official": {
            "affiliation": "Tianjin Medical University Cancer Institute and Hospital", 
            "last_name": "Yi Ba, MD.PHD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Acute neurotoxicity will be assessed the first day of oxaliplatin at every cycle given;accumulating neurotoxicity will be assessed every two weeks from the second day of first cycle until the patients out of the study. The accumulating neurotoxicity will be assessed every four weeks for 12 months or one week before second-line chemotherapy", 
            "measure": "The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity", 
            "safety_issue": "Yes", 
            "time_frame": "From the first day of chemotherapy to 12 months after study or until one week before the patients receive second-line chemotherapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024412"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Investigators assess the effect every six weeks and objective response is recorded as complete response,partial response or stable disease according to Recist 1.1", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Eevery 6 weeks, up to 24 months"
            }, 
            {
                "description": "From date of randomization until the date of first documented progression", 
                "measure": "Progress Free Survival", 
                "safety_issue": "No", 
                "time_frame": "investigators assess the effect of chemotherapy every 6 weeks ,up to 24 months"
            }, 
            {
                "description": "the patients will be followed one month after progression ,then every 3 months,up to 100 months", 
                "measure": "overall Survival", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of death from any cause, assessed up to 100 months"
            }, 
            {
                "description": "we use sf-36 to evaluated the quality of life", 
                "measure": "quality of life", 
                "safety_issue": "No", 
                "time_frame": "evaluate 1 week before chemotherapy and every 6 weeks of study. And evaluate within 4 weeks after the patients out of the study"
            }
        ], 
        "source": "Tianjin Medical University Cancer Institute and Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}